Cargando…

JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis

BACKGROUND: During severe immunosuppression or treatment with specific biological drugs, human polyomavirus JC (JCPyV) may establish a lytic infection in oligodendrocytes, leading to progressive multifocal leukoencephalopathy (PML). Beyond AIDS, which represents the most common predisposing conditio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciardi, Maria Rosa, Zingaropoli, Maria Antonella, Iannetta, Marco, Prezioso, Carla, Perri, Valentina, Pasculli, Patrizia, Lichtner, Miriam, d’Ettorre, Gabriella, Altieri, Marta, Conte, Antonella, Pietropaolo, Valeria, Mastroianni, Claudio Maria, Vullo, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014659/ https://www.ncbi.nlm.nih.gov/pubmed/32046748 http://dx.doi.org/10.1186/s12985-020-1295-5

Ejemplares similares

COS-7 and SVGp12 Cellular Models to Study JCPyV Replication and MicroRNA Expression after Infection with Archetypal and Rearranged-NCCR Viral Strains
por: Prezioso, Carla, et al.
Publicado: (2022)

Detection of human neurotropic JCPyV DNA sequence in pediatric anaplastic xanthoastrocytoma
por: Passerini, Sara, et al.
Publicado: (2023)

Reply to Henriksen, S.; Rinaldo, C.H. Should SVGp12 Be Used for JC Polyomavirus Studies? Comment on “Prezioso et al. COS-7 and SVGp12 Cellular Models to Study JCPyV Replication and MicroRNA Expression after Infection with Archetypal and Rearranged-NCCR Viral Strains. Viruses 2022, 14, 2070”
por: Prezioso, Carla, et al.
Publicado: (2022)

Human Polyomavirus JCPyV and Its Role in Progressive Multifocal Leukoencephalopathy and Oncogenesis
por: Del Valle, Luis, et al.
Publicado: (2019)

JCPyV-Induced MAPK Signaling Activates Transcription Factors during Infection
por: DuShane, Jeanne K., et al.
Publicado: (2019)

Discriminating between JCPyV and BKPyV in Urinary Virome Data Sets
por: Mormando, Rita, et al.
Publicado: (2021)

Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients
por: D’Abramo, Alessandra, et al.
Publicado: (2016)

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

Polyomavirus JCPyV infrequently detectable in adenoid cystic carcinoma of the oral cavity and the airways
por: Hämetoja, Hanna, et al.
Publicado: (2019)

The MAPK/ERK Pathway and the Role of DUSP1 in JCPyV Infection of Primary Astrocytes
por: Wilczek, Michael P., et al.
Publicado: (2021)

Specific and quantitative detection of Human polyomaviruses BKPyV and JCPyV in the healthy Pakistani population
por: Hussain, Iqra, et al.
Publicado: (2017)

Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells
por: O’Hara, Bethany A., et al.
Publicado: (2021)

The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
por: Ciardi, Maria Rosa, et al.
Publicado: (2020)

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9
por: Chou, Yi-ying, et al.
Publicado: (2016)

JCPyV VP1 Mutations in Progressive Multifocal Leukoencephalopathy: Altering Tropism or Mediating Immune Evasion?
por: Lauver, Matthew D., et al.
Publicado: (2020)

Induction of Brain Tumors by the Archetype Strain of Human Neurotropic JCPyV in a Transgenic Mouse Model
por: Del Valle, Luis, et al.
Publicado: (2021)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

IFNα and β Mediated JCPyV Suppression through C/EBPβ-LIP Isoform
por: May, Dana, et al.
Publicado: (2021)

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2021)

JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus
por: Zingaropoli, Maria A., et al.
Publicado: (2018)

JCPyV T-Antigen Activation of the Anti-Apoptotic Survivin Promoter—Its Role in the Development of Progressive Multifocal Leukoencephalopathy
por: Del Valle, Luis, et al.
Publicado: (2020)

JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients
por: Agostini, Simone, et al.
Publicado: (2021)

The differential presence of human polyomaviruses, JCPyV and BKPyV, in prostate cancer and benign prostate hypertrophy tissues
por: Shen, Chenghuang, et al.
Publicado: (2021)

PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes
por: Wilczek, Michael P., et al.
Publicado: (2021)

Human polyomavirus BKPyV and JCPyV serostatus has no impact on women´s human papillomavirus infection outcome
por: Laine, Hanna K., et al.
Publicado: (2023)

Major reduction of NKT cells in patients with severe COVID-19 pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2021)

Detection Analysis and Study of Genomic Region Variability of JCPyV, BKPyV, MCPyV, HPyV6, HPyV7 and QPyV in the Urine and Plasma of HIV-1-Infected Patients
por: Passerini, Sara, et al.
Publicado: (2022)

Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2022)

Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin
por: D'Abramo, Alessandra, et al.
Publicado: (2013)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

Efficient propagation of archetype JC polyomavirus in COS-7 cells: evaluation of rearrangements within the NCCR structural organization after transfection
por: Prezioso, Carla, et al.
Publicado: (2017)

Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
por: Prezioso, Carla, et al.
Publicado: (2022)

Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease
por: Fedele, Giorgio, et al.
Publicado: (2022)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
por: Diotti, Roberta Antonia, et al.
Publicado: (2016)

Should SVGp12 Be Used for JC Polyomavirus Studies? Comment on Prezioso et al. COS-7 and SVGp12 Cellular Models to Study JCPyV Replication and MicroRNA Expression after Infection with Archetypal and Rearranged-NCCR Viral Strains. Viruses 2022, 14, 2070
por: Henriksen, Stian, et al.
Publicado: (2022)

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
por: Ciardi, Maria R, et al.
Publicado: (2018)

Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment
por: Pietropaolo, Valeria, et al.
Publicado: (2015)

Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study
por: Russo, Gianluca, et al.
Publicado: (2021)

Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
por: Tortellini, Eeva, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qqildngnt2d5t5sc06ucnc5spf